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Increased autophagy accelerates
colchicine-induced muscle toxicity
James K Ching,1 Jeong Sun Ju,1 Sara K Pittman,1 Marta Margeta,2 and Conrad C Weihl1,*
Department of Neurology; Hope Center for Neurological Diseases; Washington University School of Medicine; St. Louis, MO USA; 2Department of Pathology;
University of California San Francisco School of Medicine; San Francisco, CA USA

1

Abbreviations: HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A; HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase;
IBMPFD, inclusion body myopathy associated with Paget disease of the bone and fronto-temporal dementia; i.p., intraperitoneal;
PBS, phosphate-buffered saline; TA, tibialis anterior

Colchicine treatment is associated with an autophagic vacuolar myopathy in human patients. The presumed
mechanism of colchicine-induced myotoxicity is the destabilization of the microtubule system that leads to impaired
autophagosome-lysosome fusion and the accumulation of autophagic vacuoles. Using the MTOR inhibitor rapamycin
we augmented colchicine’s myotoxic effect by increasing the autophagic flux; this resulted in an acute myopathy with
muscle necrosis. In contrast to myonecrosis induced by cardiotoxin, myonecrosis induced by a combination of rapamycin
and colchicine was associated with accumulation of autophagic substrates such as LC3-II and SQSTM1; as a result, autophagic vacuoles accumulated in the center of myofibers, where LC3-positive autophagosomes failed to colocalize with
the lysosomal protein marker LAMP2. A similar pattern of central LC3 accumulation and myonecrosis is seen in human
patients with colchicine myopathy, many of whom have been treated with statins (HMGCR/HMG-CoA reductase inhibitors) in addition to colchicine. In mice, cotreatment with colchicine and simvastatin also led to muscle necrosis and LC3
accumulation, suggesting that, like rapamycin, simvastatin activates autophagy. Consistent with this, treatment of mice
with four different statin medications enhanced autophagic flux in skeletal muscle in vivo. Polypharmacy is a known risk
factor for toxic myopathies; our data suggest that some medication combinations may simultaneously activate upstream
autophagy signaling pathways while inhibiting the degradation of these newly synthesized autophagosomes, resulting
in myotoxicity.

Introduction
Most cases of toxic myopathy are the consequence of drugs
commonly used for therapeutic interventions.1 Muscle tissue is
particularly vulnerable to drug-associated toxicity because of its
relative abundance, high blood flow, and metabolic rate. One
example of a toxic myopathy is colchicine-induced myopathy.2
Colchicine is commonly used for the treatment of gouty arthritis,
often at high initial doses. Colchicine myopathy is characterized
by myalgias, muscle weakness, and occasional rhabdomyolysis.2
In addition to myopathy, muscle tissue demonstrates the accumulation of autophagic vacuoles.2 The mechanism of colchicine-associated muscle toxicity is poorly understood. Colchicine
destabilizes microtubules, which are required for both endosomal
and autophagosomal maturation,3 the resultant accumulation of
endosomal and autophagic debris has been previously proposed
as the pathogenic mechanism for colchicine myopathy.3
Macroautophagy (autophagy) is the bulk degradation of cytoplasmic proteins and organelles.4 This process includes multiple
steps, many of which require intact microtubules: (1) phagophore

initiation and expansion, (2) autophagosome formation, and
(3) autophagosome fusion with acidic lysosomes.5 Skeletal muscle
is sensitive to stimuli that activate autophagic degradation, such
as nutrient deprivation and exercise.6,7 In addition, several drugs
such as rapamycin activate autophagy in mouse skeletal muscle.8
If the accumulation of autophagic debris due to impaired microtubule trafficking is indeed the pathogenic mechanism of colchicine-induced myopathy, it would be reasonable to expect that
inducing autophagy in the setting of colchicine treatment should
exacerbate the disease pathology/progression.
Statins (HMGCR [3-hydroxy-3-methylglutaryl-CoA reductase] inhibitors) are among the most commonly prescribed medications for the reduction of cholesterol,9 but their use is limited
by muscle toxicity. Statin use has been associated with muscle
pain, exercise intolerance, muscle weakness, and rhabdomyolysis.10 Interestingly, the risk of statin-associated muscle toxicity
increases with age and medication usage.10 In fact, many acute
cases of muscle toxicity have been reported in patients concomitantly taking statins and colchicine.11-20 Statins reportedly induce
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Similarly, we found that i.p. colchicine at the same dose for 40 d caused
myopathy with rare vacuoles, and the
accumulation of autophagic markers
LC3 and SQSTM1 in mouse skeletal
muscle (Fig. 1; see Fig. S1 for isotype control IgG staining). In some
cases, LC3 and SQSTM1 colocalized to the central region of a myofiber (Fig. 1E). To investigate whether
autophagy induction accelerated colchicine-induced muscle toxicity, we
treated 24 mice for 10 d with vehicle,
i.p. colchicine (0.4 mg/kg/d), i.p.
rapamycin (10 mg/kg/d), or i.p. colchicine and rapamycin combination;
following treatment, we analyzed the
tibialis anterior (TA) and quadriceps
muscles by routine histochemistry.
TA and quadriceps muscles from
mice treated for 10 d with colchicine
or rapamycin alone appeared similar
to control mouse muscle when visualized via H&E or congo red, with
no evidence of myopathic features
(not shown). Therefore, in the case
of colchicine, treatment periods longer than 10 d are necessary to induce
the vacuolar changes seen in colchicine myopathy. In contrast, mice
treated with 0.4 mg/kg/d i.p. colchicine and 10 mg/kg/d i.p. rapamycin
for 10 d showed abnormal fibers
with rare vacuolar structures, as evidenced by H&E, congo red, acid
phosphatase, and succinate dehyFigure 1. Chronic colchicine treatment leads to an autophagic vacuolar myopathy in mouse skeletal
drogenase staining (Fig. 2A–D). To
muscle. (A and B) H&E of TA muscle from mice treated with (A) vehicle or (B) 0.4 mg/kg/d colchicine i.p.
confirm that the observed abnormal
for 40 d. Black arrow denotes a vacuolated fiber. (C) TA muscle similar to (B), immunostained with antifibers were necrotic and that we
SQSTM1 or (D) anti-LC3 antibody. DAPI-stained nuclei are blue. White arrow denotes the accumulation of
autophagic proteins. Scale bar: 50 µm. (E) A single myofiber co-immunostained with antibodies to LC3;
had indeed accelerated the muscle
SQSTM1; and merged LC3 (green) and SQSTM1 (red). Scale bar: 5 µm. The sarcolemma of some fibers is
toxicity induced by colchicine, we
outlined.
immunostained muscle sections with
an antibody to complement c5b9, a
autophagy in vitro,21,22 lending credence to our hypothesis that marker of necrotic muscle fibers (Fig. 2E–H). The percentage
active autophagy is the potential driving force behind colchicine- of fibers that stained positive for c5b9 increased significantly in
induced muscle toxicity. To explore the impact of enhanced auto- mice treated with both drugs compared with vehicle-, rapamyphagy in colchicine-induced myopathy, we evaluated muscle cin-, or colchicine-treated groups (Fig. 2I). These data suggest
pathology in mice treated with rapamycin or simvastatin in the that enhancing autophagy with rapamycin augments the pathosetting of colchicine.
genesis of colchicine, leading to a necrotic autophagic myopathy.
Colchicine plus rapamycin-treated mouse muscle accumuResults
lates autophagic structures
Given that we enhanced autophagosome biogenesis with
Rapamycin accelerates colchicine-induced muscle toxicity
rapamycin and at the same time blocked autophagosome degPrevious studies have evaluated the toxicity of colchicine in a radation with colchicine, we reasoned that the pathological
rodent model and found that four weeks of intraperitoneal (i.p.) changes seen in the skeletal muscle of colchicine plus rapamycincolchicine at a dose of 0.4 mg/kg/d caused a vacuolar myopathy.3 treated mice may be due to the accumulation of nondegraded

©2013 Landes Bioscience. Do not distribute.
Figure 2. Rapamycin treatment augments pathology in a mouse colchicine myopathy model. Histochemical analysis of TA muscle from mice treated
with colchicine (0.4 mg/kg/d) and rapamycin (10 mg/kg/d) for 10 d. (A and B) congo red, (C) acid phosphatase, and (D) succinate dehydrogenase staining
demonstrate a myopathy with scattered necrotic fibers (arrows). (E and H) TA muscle from (E) vehicle-, (F) rapamycin-, (G) colchicine- or (H) colchicine
plus rapamycin-treated mice immunostained with an antibody to complement c5b9; arrows denote necrotic fibers. (I) Quantification of the percentage
of c5b9-positive fibers per 20× field in muscle from mice treated with vehicle, rapamycin, colchicine or colchicine plus rapamycin for 10 d. *P < 0.05, the
Student unpaired t-test between treatment and control. n = 5/condition. Scale bar: 50 µm.
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autophagosomes. To test this hypothesis, we immunoblotted TA
muscle lysates from vehicle-, rapamycin-, colchicine- or colchicine plus rapamycin-treated mice for the autophagic substrates
SQSTM1 and LC3 (Fig. 3A). Upon phagophore formation,
LC3-I can become lipidated and attach to the growing phagophore membrane as LC3-II.6 SQSTM1 and LC3-II levels were

increased in colchicine-treated mice and to a greater extent in
colchicine plus rapamycin-treated mouse muscle (Fig. 3A).
Ubiquitinated proteins can be degraded via autophagy and are
thus autophagic substrates.4 Consistent with this, the level of
ubiquitinated proteins was elevated in colchicine plus rapamycintreated mouse muscle (Fig. 3A). In addition, two other autophagic
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Figure 3. Autophagic substrates accumulate in the muscle of colchicine plus rapamycin-treated mice. (A) Immunoblot using antibodies to LC3, SQSTM1,
ubiquitinated proteins, BNIP3, BECN1, and actin of TA muscle from 3–4 mo old mice treated i.p. with vehicle, 10 mg/kg/d rapamycin (rapa), 0.4 mg/
kg/d colchicine (colch), or both drugs (colch+rapa) for 10 d. Blot is a representative of 3 independent experiments. (B) Quantitative PCR analysis of RNA
from TA muscle obtained from 3–4 mo old mice treated i.p. with vehicle (veh) or colchicine+rapamycin (colc+rap) for 10 d. Data are represented as fold
change as compared with vehicle treatment. P values were obtained from the Student unpaired t-test between treatment and control. n = 3/condition.
(C) Immunoblot using antibodies described above in addition to RIPK1 kinase and GAPDH of TA muscle injected with vehicle or 100 µL of 12 µM cardiotoxin and harvested 2 d later. (D) TA muscle from vehicle-, rapamycin-, colchicine-, or colchicine plus rapamycin-treated mice immunostained with an
antibody to LC3 or SQSTM1. DAPI-stained nuclei are blue; the sarcolemma of some fibers is outlined. Scale bar: 50 µm.
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proteins, BNIP3 and BECN1/
Beclin 1, were increased in TA muscle lysates from mice treated with
both colchicine and rapamycin compared with mice treated with vehicle,
rapamycin alone, or colchicine alone
(Fig. 3A). The accumulation of autophagic substrates such as LC3-II and
SQSTM1 may not solely be caused
by a decrease in their degradation but
also as a result of enhanced transcription of the corresponding genes. To
test this, we performed quantitative
RT-PCR expression analysis using
total RNA isolated from TA muscle
obtained from vehicle-treated and
colchicine plus rapamycin-treated
mice (Fig. 3B). Consistent with
enhanced autophagosome biogenesis, the expression of MAP1LC3A,
MAP1LC3B, and SQSTM1 were
increased by ~3–4 fold (Fig. 3B). In
addition, the expression of the lysosomal/endosomal protein LAMP1
was increased by ~3 fold (Fig. 3B).
In contrast, the expression of BNIP3
was not different between groups
(Fig. 3B).
We do not think that the accumulation of autophagic substrates was a
consequence of muscle necrosis, since
muscle treated for two days with cardiotoxin showed a modest change
in LC3-II levels and a decrease
in SQSTM1 levels (Fig. 3C).
Immunohistochemical
staining
of LC3, SQSTM1, and BNIP3 in
cardiotoxin-treated muscle demonstrated that these autophagic markers were indeed altered in myofibers
and not infiltrating cells (Fig. S2).
Interestingly, BECN1 and BNIP3, as
well as the necrotic signaling kinase
RIPK1, were elevated after two days
of cardiotoxin-induced muscle injury
(Fig. 3C).
To define the localization of
Figure 4. Immunohistochemistry of TA muscle from mice treated with vehicle (left panels) or colchicine
accumulated autophagic proteins in
and rapamycin (right panels) for 10 d using an anti-CAV3/caveolin 3 antibody (green) and antibodies to
treated mouse muscle, we performed
LC3, LAMP2, SQSTM1, and BNIP3, all in red. Scale bar: 50 µm.
immunohistochemistry with antibodies to LC3, SQSTM1, and BNIP3; in
addition, we used an antibody to the lysosomal marker, LAMP2. puncta in colchicine alone-treated muscle, but other autophagic
All autophagic markers were increased in colchicine plus rapamy- markers were not increased above that seen with vehicle or rapamycin-treated mouse muscle when compared with muscle from the cin treatment (Fig. 3D). Interestingly, these autophagic proteins
control, rapamycin-, and colchicine-treated mice (Fig. 3D and not were localized to the central region of myofibers (Fig. 4) rather
shown). Scattered fibers showed an increase in SQSTM1-positive than throughout the sarcoplasm, as seen in cardiotoxin-treated
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not impaired (Fig. 5B). Finally,
SQSTM1 and ubiquitinated proteins
strongly colocalized, indicating that
association of SQSTM1 with ubiquitinated substrates was not affected
(Fig. 5C). Electron microscopy of
similarly treated muscle demonstrated the accumulation of vacuolated structures, many of which had
double membranes and contained
cellular contents, consistent with
autophagosomes. These structures
were found within the central region
of fibers between myofibrils (Fig. 5D
and E).
Simvastatin-induced autophagy
accelerates colchicine-induced muscle toxicity
We previously reported the pathological features of seven patients with
colchicine-associated
myopathy.23
Polypharmacy is a well-established
risk factor for colchicine muscle
toxicity,2 and commonly prescribed
drugs, such as the cholesterol-lowering agents statins, are likely to play
an important role. Indeed, two of
seven patients in our original patient
cohort (#22 and #25) and two of
two patients diagnosed with colchicine myopathy since completion
of that study (four of nine or 44%
in total) were on both colchicine
and a statin at the time of muscle
biopsy. Immunohistochemical staining of these patients’ muscle biopsies showed a pattern of LC3 and
SQSTM1 deposition in myofibers
similar to that seen in colchicine
plus rapamycin-treated mice (a representative biopsy is shown in Fig. 6;
compare with a muscle sample from
control patient with no muscle disFigure 5. Autophagic structures are centrally located in the myofibers of colchicine plus rapamycintreated mice. (A) A single myofiber co-immunostained with antibodies to LC3, LAMP2, and merged LC3
ease, Fig. S3). A detailed quantifica(green) and LAMP2 (red). (B) A single myofiber co-immunostained with antibodies to LC3, SQSTM1, and
tion of the percentage of LC3- and
merged LC3 (green) and SQSTM1 (red). (C) A single myofiber co-immunostained with antibodies to ubiqSQSTM1-immunopositive
myouitin, SQSTM1, and merged ubiquitin (green) and SQSTM1 (red). DAPI-stained nuclei are blue; the sarcofibers in these human specimens
lemma of a single fiber is outlined. Scale bar: 5 µm. (D and E) Electron microscopy images of TA muscle
has been previously reported.23 We
from mice treated with colchicine and rapamycin. Arrows denote autophagosomes. Scale bar: 500 nm.
therefore reasoned that statin medications, like rapamycin, may accelermuscle (Fig. S2). To further characterize this, we performed ate and/or potentiate colchicine toxicity.
several immunofluorescence colocalization studies. As expected,
To test this, mice were divided into four treatment groups of
LC3 and LAMP2 did not colocalize in colchicine plus rapamycin- six mice each: vehicle alone, 0.4 mg/kg/d colchicine, 10 mg/kg/d
treated mouse muscle, consistent with a failure in autophagosome- simvastatin, or both colchicine and simvastatin daily for 10 d.
lysosome fusion (Fig. 5A). In contrast, SQSTM1 colocalized Following treatment, mice were sacrificed and TA and quadriceps
with LC3, suggesting that the loading of autophagosomes was muscles were analyzed via western blot, routine histopathology
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and immunohistochemistry. Similar
to the muscle pathology seen in mice
treated with colchicine plus rapamycin (Figs. 2 and 3) and human
muscle pathology in patients treated
with colchicine plus statin (Fig. 6),
muscle from mice treated with colchicine plus simvastatin displayed
myopathic features, with scattered
necrotic fibers and LC3 accumulation within the center of myofibers
(Fig. 7B and D). This pattern was
not seen in the other treatment
groups, including the group treated
with simvastatin alone (Fig. 7A and
C). To confirm necrosis and quantify the augmentation of colchicine
toxicity by simvastatin, we immunostained tissue with an antibody to
c5b9 and quantified the percentage
of positive fibers (Fig. 7E and F).
Similar to colchicine plus rapamycin,
colchicine plus simvastatin treatment
resulted in an increase in necrotic
Figure 6. Accumulation of autophagic debris in the muscle biopsy from a patient concurrently treated
fibers when compared with vehicle-,
with colchicine and a statin. H&E staining of frozen tissue (A) and toluidine blue staining of EPONcolchicine- or simvastatin-treated
embedded tissue (B) demonstrate disruption of the myofibrillary apparatus (arrows in A) and accumulamice (Fig. 7G). Immunoblotting for
tion of the vacuolated material (arrowheads in B) in the center of myofibers. Immunohistochemistry for
autophagic substrates in colchicine
LC3 (C) or SQSTM1 (D) on formalin-fixed, paraffin-embedded tissue shows that vacuolated central areas
contain LC3- and SQSTM1-positive autophagic material. Scale bar: 20 µm.
plus simvastatin-treated mouse muscle also demonstrated an increase
in LC3-II, SQSTM1, and ubiquitiDiscussion
nated proteins when compared with any of the control groups
The myotoxic effect of colchicine is well known, but it has
(Fig. 7H); these data raise the possibility that, like rapamycin,
been difficult to pinpoint its pathogenic mechanism. The bulk
statins activate autophagy.
of the relevant mechanisms proposed so far to explain colchicineStatins induce autophagy in mouse skeletal muscle
Previous studies have demonstrated that statins can induce induced muscle toxicity hinge on the disruption of the microtuautophagy in cell culture models of skeletal muscle,21,22 but it has bule network.2,3 In this study, we report data which support an
not been established whether this occurs in vivo in mature skel- expansion of the paradigm regarding the mechanism of colchicineetal muscle. To evaluate this, we treated mice with four different induced muscle toxicity from mere disruption of the microtubule
statin drugs (simvastatin, atorvastatin, lovastatin, and pravas- network to a functional and/or synergistic relationship between
tatin) for 7 d prior to isolating skeletal muscle and performing an colchicine and autophagy induction. We have shown that mice
immunoblot using an anti-LC3 antibody. To confirm that these treated for 10 d with both colchicine and autophagic inducers
drugs truly enhanced autophagic flux, we treated similar mice such as rapamycin or simvastatin display (1) increased accumuwith 0.4 mg/kg colchicine on days 6 and 7 and then harvested lation of autophagic substrates and ubiquitinated proteins; and
TA muscles for immunoblot. LC3-II levels were unchanged in (2) worsening of the colchicine-induced muscle pathology when
muscle from mice treated with statins alone when compared with compared with mice injected with colchicine alone. Thus, the
muscle from vehicle-treated mice. As we have previously demon- emerging hypothesis is that colchicine-induced muscle toxicity
strated, there was accumulation of LC3-II in mice that received is a result of autophagic vacuole build-up due to enhanced autocolchicine for 2 d, indicating a block in basal autophagy (Fig. 8A phagosome formation and impaired autophagic degradation; this
and B).8 Consistent with an increase in autophagic flux, skeletal possibility is supported by the fact that autophagic markers LC3
muscle lysates from mice receiving a statin for 7 d and colchi- and SQSTM1 robustly accumulate in the muscle of patients with
cine on days 6 and 7 displayed increased accumulation of LC3-II colchicine-induced autophagic vacuolar myopathy.23
when compared with the colchicine group, suggesting that statins
Colchicine and chloroquine have both been associated with
enhance autophagic flux in vivo.8 The increase in flux is repre- toxic vacuolar myopathies.1 In the case of chloroquine, lysosomal
sented as the ratio of LC3-II to actin from four mice per condi- de-acidification is the presumed mechanism by which autotion (Fig. 8B).
phagic vacuoles accumulate and fail to be degraded.24 Previous

rodent models of chloroquine-induced myopathy have treated
mice for several weeks with chloroquine to induce pathology.25
Interestingly, dennervation of muscle hastens the development of
an autophagic myopathy resulting in pathology over the course
of days rather than weeks.25 Dennervation is a potent inducer
of muscle atrophy and autophagy,8,26,27 an increase in autophagy
in the setting of impaired autophagic degradation may explain

the synergism between chloroquine
treatment and dennervation in
experimental models of chloroquine
myopathy.
Many vacuolar myopathies are
due to mutations in proteins associated with lysosomal function and
accumulate autophagic proteins
within the myofiber similarly to the
pathology seen in colchicine-associated myopathy. For example, Danon
disease, Pompe disease, and X-linked
myopathy with excessive autophagy
all accumulate autophagic debris.28
Whether the activation of autophagy
is beneficial or detrimental for these
diseases is not known. We recently
demonstrated that enhancing autophagy with rapamycin worsened the
vacuolar pathology, protein aggregate accumulation and weakness in
a mouse model of inclusion body
myopathy associated with Paget
disease of the bone and fronto-temporal dementia (IBMPFD).29 IBMPFD is caused by mutations
in valosin containing protein, which is required for maturation
of autophagosomes to autolysosomes.30 Interestingly, in the case
of IBMPFD, X-linked myopathy with excessive autophagy and
sporadic inclusion body myositis, MTORC1 activity is diminished, suggesting enhanced autophagosome formation.29,31,32 The
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Figure 7. Simvastatin treatment augments pathology in a mouse colchicine
myopathy model. H&E staining of TA
muscle from mice treated for 10 d with
(A) simvastatin (10 mg/kg/d) or (B) colchicine (0.4 mg/kg/d) and simvastatin
(10 mg/kg/d). (C and D) TA muscle from
(C) simvastatin- or (D) colchicine plus
simvastatin-treated mice immunostained with an antibody to LC3. (E and
F) TA muscle from (E) simvastatin- or
(F) colchicine plus simvastatin-treated
mice immunostained with an antibody to c5b9. Open arrows denote
necrotic fibers and closed arrows
LC3-positive fibers. Scale bar: 50 µm.
(G) Quantification of the percentage
of c5b9-positive fibers per 20× field
in muscle treated with vehicle, simvastatin, colchicine, or colchicine plus
simvastatin for 10 d. *P < 0.05, the
Student unpaired t-test between treatment and control. n = 6/condition.
(H) Immunoblot of TA muscle from 3–4
mo old mice treated i.p. with vehicle,
10 mg/kg/d simvastatin (simv), 0.4 mg/
kg/d colchicine (colch), or both drugs
(colch+simv) for 10 d. Blot is a representative of 3 independent experiments.

Materials and Methods

Figure 8. Statins enhance autophagic flux in mouse muscle in vivo.
Five cohorts of mice were treated with vehicle or 1 of 4 different statin
medications: simvastatin (simv), atorvastatin (atorva), lovastatin (lova) or
pravastatin (prava) i.p., at a dosage of 10 mg/kg/d for 7 d. On days 6 and 7,
some mice were also administered 0.4 mg/kg/d colchicine to block autophagosome degradation. (A) Immunoblots of mouse TA muscle lysates
using antibodies for LC3 and actin. (B) Densitometric quantification of
LC3-II/actin from immunoblots. (+) indicates with colchicine treatment.
*P < 0.05, Student unpaired t-test between treatment and colchicine
groups. n ≥ 4 mice/condition.

Antibodies and reagents for mouse studies
Antibodies for BECN1 (Cell Signaling Technologies, 3738),
GAPDH (Cell Signaling Technologies, 2118), LAMP2 (Santa
Cruz Biotechnology, sc-18822), BNIP3 (Abcam, ab10433), Actin
(Sigma, A2066), LC3B (Sigma, L7543) for western blotting, LC3
(Nanotools, 0231-100/LC3-5F10) for immunostaining, RIPK1/
RIP1 (BD Transduction Laboratories, 610458), c5b9 (Dako,
M0777), and antibodies to SQSTM1 (Proteintech,184201-AP) for western blotting, and to SQSTM1 (Sigma, P0067) for
immunostaining were obtained from the indicated sources. For
the autophagic assessment of necrotic fibers in Figure S2, the
VECTOR M.O.M. immunodetection Kit Flourescein (Vector
Laboratories, FMK-2001) was used to quench endogenous background IgG. Rapamycin (LC Laboratories R-5000) and cardiotoxin (Sigma, C9759) were also purchased. Simvastatin (1965),
atorvastatin (3776), lovastatin (1530), and pravastatin (2318)
were obtained from TOCRIS.
Animals and drug treatments
All experiments were conducted using 3–4 mo old C57BL/6
mice from Jackson Laboratory. Animal studies were approved by
the Animal Studies Committee of Washington University School
of Medicine. Upon arrival, mice were housed in a temperaturecontrolled environment with 12 h light/dark cycles, where they
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current study lends further support to a mechanism of disease in
which activation of autophagy drives the vacuolar pathology in
some myopathies.
Statins initiate autophagy in cultured cells.21,33 The mechanism by which statins induce autophagy likely relates to their
mechanism of action within the HMGCR pathway. Specifically,
depletion of geranylgeranyl diphosphate by statins and bisphosphonates can induce autophagy.21,34 Moreover, farnesyl transferase inhibitors and geranylgeranyl transferase inhibitors both
induce autophagy in vitro.35,36 Our studies confirm these cell culture models and demonstrate that statins can effectively enhance
autophagic flux in vivo in mouse skeletal muscle. In this context,
it is worth noting that UCSF muscle pathology practice has seen
a sharp increase in the number of colchicine and hydroxychloroquine myopathy cases in the last 5–6 y, coinciding with a large
increase in statin use (based on a CDC survey entitled “Health,
United States, 2010,” the percentage of statin-using adults [≥ 45 y
of age] increased from 2% in the period of 1988–1994 to 25% in
the period 2005–2008, and is likely even higher today).
Risk factors for statin muscle toxicity are higher dosages,
concomitant use of certain drugs that can inhibit statin metabolism, and more recently polymorphisms in the gene SLCO1B1/
OATP1B1 that encodes solute carrier organic anion transporter
family, member 1B1, and mediates the uptake of various drugs
including statins.37,38 It is conceivable that the accelerated muscle
pathology seen in our studies is due to increased statin drug concentration in the setting of colchicine administration. However,
based on the findings of our study, we propose that mutations or
polymorphisms in genes within the autophagy pathway may also
be risk factors for statin myotoxicity.

and the mouse autophagy RT1 Profiler PCR array (Qiagen,
330231 PAMM-084ZA), which contains primers for the expression of 84 autophagy genes arranged in a staggered format. Data
were normalized to the average of 4 housekeeping genes, Gapdh,
Actb/β-actin, B2m/β2-microglobulin, and Gusb/β-glucoronidase
and expressed in terms of 2-ΔΔCT.
Histochemistry, immunohistochemistry, and electron
microscopy
Isolated muscle was mounted using tragacanth gum (Sigma,
G1128) and quick frozen in liquid nitrogen-cooled 2-methylbutane. Samples were stored at −80 °C until sectioning into 10-µm
sections. H&E, congo red, acid phosphatase, and succinate
dehydrogenase staining was performed as previously described.39
Briefly, muscle sections were affixed to slides incubated for 10
min in ice-cold acetone, mounted with Prolong Gold + DAPI
(Invitrogen, P36931), and examined using a fluorescence microscope (Nikon 80i upright+ and Roper Scientific EZ monochrome CCD camera with deconvolution software analysis [NIS
Elements, Nikon]). Nonfluoresent images were taken with a 5
megapixel color CCD (Nikon). For electron microscopy, TA
muscle was harvested, rinsed briefly in PBS and then placed
immediately in Karnovsky fixative40 at 4 °C for 24 h. Fixed
muscle was embedded in plastic and sectioned for EM imaging. Images were taken using a Jeol 1400 and a Gatan Orius 832
Digital Camera. Image processing and analysis were done with
(NIS Elements 4.0) software and Adobe Photoshop.
Quantification of necrotic fibers
The percentage of c5b9-positive fibers was quantified per 20×
field. Twenty randomly selected microscopy fields from 10 TA
muscles from 5 mice/condition were selected and the total number of myofibers and the number of immunoreactive fibers were
counted and expressed as a percentage.
Human subjects
Study design was reviewed and approved by the University
of California San Francisco Committee on Human Research;
the informed consent requirement was waived given the noninvasive nature of the study and a minimal potential for harm to
study participants. Immunoperoxidase staining for LC3 (mouse
monoclonal antibody, clone 5F10, Nanotools, 0231-100) and
SQSTM1 (guinea pig polyclonal antibody, Progen Biotechnik,
GP62) was performed on formalin-fixed, paraffin-embedded tissue samples using the Ventana Benchmark XT automated slide
preparation system as described previously.23 Images were taken
with a DP72 digital camera on a BX41 bright-field light microscope using cellSens Entry 1.6 software (all by Olympus) and
were edited with Adobe Photoshop CS5 Version 12.1.32.
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received food and water ad libitum. All drugs were injected intraperitoneally. Rapamycin was dissolved in 100% ethanol at 62.5
mg/ml, stored at −20 °C, and diluted to 2.5 mg/ml in vehicle
(5% PEG 400, 5% Tween 80, and 4% ethanol) just before injection. Colchicine was dissolved in water, stored at −20 °C as a
stock solution at a concentration of 4 mg/ml, and diluted to 0.1
mg/ml before injection. Simvastatin, atorvastatin, lovastatin, and
pravastatin were administered at a dose of 10 mg/kg body weight.
Simvastatin and lovastatin were dissolved in 100% ethanol and
stored at −20 °C as stocks; on the day of experiment, they were
diluted with PBS immediately prior to injection. Atorvastatin
was dissolved in DMSO and stored as stock solution, which was
diluted with PBS immediately prior to injection. Pravastatin was
dissolved in water. For all drug treatments, control mice received
equal volumes of respective vehicles. Mice were subjected to i.p.
injection of both rapamycin (10 mg/kg body weight) and colchicine (0.4 mg/kg body weight) daily for 10 d. Age-match littermates were injected with vehicle (5% Tween 80, 5% polyethylene
glycol, and 4% ethanol), rapamycin alone, or colchicine alone
as controls. Similar experiments were performed with simvastatin (10 mg/kg body weight) in place of rapamycin. Cardiotoxin
(from Naja mossabica mossambica) was dissolved in water and
stored at -20 °C as stock solution, which was diluted in PBS to a
working concentration of 12 µM prior to experiment. For each
mouse, tibialis anterior muscles were injected with 100 µL of
12 µM cardiotoxin and muscles were harvested 2 d later.
Western blotting
Muscle tissues were homogenized using RIPA lysis buffer
(50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.25%
Na-deoxycholate, 1 mM EDTA) supplemented with protease
inhibitor cocktail (Sigma-Aldrich, s8820-20TAB) and then centrifuged at 14,000 g for 10 min. Protein concentrations were determined using BCA protein assay kit (Thermo Fisher Scientific,
23225). Aliquots of lysates were solubilized in Laemmli sample
buffer and equal amounts of proteins were separated by 12%
SDS-PAGE. Proteins were transferred to nitrocellulose membrane and the membrane was blocked with 5% nonfat dry milk
in phosphate-buffered saline (PBS) for 1 h. The membrane was
then incubated with primary antibodies in 5% nonfat dry milk
overnight at 4 °C; after incubation with the appropriate secondary antibody conjugated with horseradish peroxidase, enhanced
chemiluminescence (ImmunoPure, 31430) was used for protein
detection. If necessary, blots were stripped using Re-blot strong
solution (Millipore, 2504) and reprobed with the appropriate
antibodies. Autoradiographs of immunoblots were scanned using
an Epson 636 Expression scanner; immunoblots were obtained
using the G:BoxChemi XT4, Genesys Version 1.1.2.0 (Syngene).
Gene expression analyses
Total RNA was isolated from TA muscle with SV Total RNA
isolation kit (Promega, Z3100) according to the manufacturer’s
instructions. The concentration and quality of the total RNA
isolated was determined using a Nanodrop spectrophotometer.
cDNA was synthesized using the RT1 First Strand kit (Qiagen,
330401). Gene expression levels were analyzed by real-time PCR
on an Applied Biosystems model 7500 (software v2.0.5) using the
RT1 SYBER Green ROX qPCR mastermix (Qiagen, 330522)
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